Climb Bio, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission for the period ended June 30, 2026, disclosing financial results, risk factors, and operational updates as a clinical-stage biopharmaceutical company.

Key Highlights

  • Shares outstanding: As of July 31, 2026, Climb Bio had 57,436,255 shares of common stock, $0.0001 par value per share, outstanding.
  • Company classification: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • No product revenue: The company disclosed it "currently has no source of product revenue and may never become profitable."
  • Continued losses expected: Climb Bio disclosed it "has incurred significant losses since our inception and expects to continue incurring substantial losses for the foreseeable future."
  • Private placement noted: The filing references proceeds from a private placement completed in April 2026 as part of its capital resources.
  • Product candidates: The filing references budoprutug and CLYM116 as pipeline product candidates under development.

Climb Bio's Q2 2026 Quarterly Disclosure: Financial Position and Pipeline Status

Climb Bio, Inc. (CLYM on The Nasdaq Global Market) submitted its Form 10-Q covering the quarterly period ended June 30, 2026. The company is incorporated in Delaware, headquartered at 20 William Street, Suite 145, Wellesley Hills, MA 02481, and carries Commission File Number 001-40708. According to the filing, the company confirmed it has filed all required reports during the preceding 12 months and has submitted all required Interactive Data Files electronically.

The filing states that Climb Bio has no source of product revenue and that its future success is "dependent on the regulatory approval and commercialization of our product candidates." The company disclosed that its pipeline includes budoprutug and CLYM116, noting that forward-looking statements in the report cover the anticipated timing of investigational new drug application submissions and comparable foreign applications for both candidates. All such statements are the company's own and are expressly subject to its cautionary language regarding risks and uncertainties.

Among the risk factors disclosed, the company cited the possibility that it may need to "delay, reduce, or discontinue our product candidate development programs, commercialization efforts, or other operations" if unable to access capital on acceptable terms. The filing also highlighted that clinical development in immunology and autoimmune diseases "presents inherent challenges, such as disease heterogeneity, variable clinical course, and evolving regulatory expectations for clinically meaningful endpoints." The company noted that a private placement completed in April 2026 is included in its assessment of capital resources, though specific financial figures from the balance sheet were not reproduced in the extracted text provided.

What Was Disclosed

Climb Bio filed its Q2 2026 quarterly report disclosing share count, company classifications, the absence of product revenue, ongoing net losses, pipeline candidates budoprutug and CLYM116, and a broad set of operational and regulatory risk factors.